

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.USTO.GOV

ATTACHMENT TO "NOTICE TO COMPLY WITH REQUIREMENTS...SEQUENCE DISCLOSURES"

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

- 1. Electronically submitted through EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. Mailed to:

MAY 1 0 2002

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

- Mailed by Federal Express, United Parcel Service or other delivery service to:
   U. S. Patent and Trademark Office
   2011 South Clark Place
   Customer Window, Box Sequence
   Crystal Plaza Two, Lobby, Room 1B03
   Arlington, Virginia 22202
- 4. Hand Carried directly to the Customer Window at:
  2011 South Clark Place
  Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
  Arlington, Virginia 22202



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/900,345

07/06/2001

Ian Hector Frazer

10338-5US (2423066/VPA)

**CONFIRMATION NO. 4929** 

000570 AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P. ONE COMMERCE SQUARE 2005 MARKET STREET, SUITE 2200 PHILADELPHIA, PA 19103 FORMALITIES LETTER

\*OC000000007296948\*

Date Mailed: 01/11/2002

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
of the sequence listing information recorded in computer readable form is identical to the written (on paper
or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

**Customer Service Center** 

Initial Patent Examination Division (203) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

HESEBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST OF ASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE NDICATED BELOW.

BY: Nelene Gabel Date: May 1, 2002

<u>PATENT</u>

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Patent Application

: ATTENTION:

of Ian Hector Frazer et al.

: BOX SEQUENCE

Conf. No.:

4929

Appln. No.:

09/900,345

Filed:

July 6, 2001

For:

METHOD AND POLYNUCLEOTIDES

: Attorney Docket

FOR DETERMINING TRANSLATIONAL

: No. **10338-5 US** 

EFFICIENCY OF A CODON

: (2423066/VPA)

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

- () I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively are the same.
- ( ) I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(g) does not include new matter.
- () I hereby state that the submission filed in accordance with 37 C.F.R. §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
- (X) I hereby state that the amendments, made in accordance with 37 C.F.R. §1.825(a), included in the initial/substitute sheet(s) of the Sequence Listing are supported by the application as filed in the original Sequence Listing (fields <220> <223> of the nucleic acid sequences) at pages i through cci and in the original Declaration (relating to priority application No. PCT/AU00/00008). I hereby state that the substitute sheets(s) of the Sequence Listing do not include new matter.

- (X) I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(b), is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), contains identical data to that originally filed.

Respectfully submitted,

IAN HECTOR FRAZER ET AL.

May 7, 2002 By:

ALAN S. NADEL

Registration No. 27,363

AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P.

Customer No. 000570 One Commerce Square

2005 Market Street - Suite 2200

Philadelphia, PA 19103

Telephone: (215) 965-1200

**Direct Dial: (215) 965-1280** 

Facsimile: (215) 965-1210

E-Mail: anadel@akingump.com

ASN/KMP/hg Enclosures